Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody

References

• Agarwal R, Jindal SK. (2008). Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med 19:227–35.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. (2013). Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65:36–48.
   PubMed Web of Science ®Google Scholar
• Chen SS, Yin ZF, Chen T, et al. (2017). Development of a non-infectious rat model of acute exacerbation of idiopathic pulmonary fibrosis. J Thorac Dis 9:96–105.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Allison J, et al. (2006). Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55:420–6.
   PubMed Web of Science ®Google Scholar
• Desmyter A, Spinelli S, Roussel A, Cambillau C. (2015). Camelid nanobodies: killing two birds with one stone. Curr Opin Struct Biol 32:1–8.
   PubMed Web of Science ®Google Scholar
• Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. (1993). Naturally occurring antibodies devoid of light chains. Nature 363:446–8.
   PubMed Web of Science ®Google Scholar
• He X, Wang S-M, Yin ZF, et al. (2017). Identification of a nanobody specific to human pulmonary surfactant protein A. Sci Rep 7:1412.
   PubMed Web of Science ®Google Scholar
• Iyer R, Hsia CC, Nguyen KT. (2015). Nano-therapeutics for the lung: state-of-the-art and future perspectives. Curr Pharm Des 21:5233–44.
   PubMed Web of Science ®Google Scholar
• Judd LL, Schettler PJ, Brown ES, et al. (2014). Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry 171:1045–51.
   PubMed Web of Science ®Google Scholar
• Kondoh Y, Taniguchi H, Kawabata Y, et al. (1993). Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 103:1808–12.
   PubMed Web of Science ®Google Scholar
• Koshkaryev A, Sawant R, Deshpande M, Torchilin V. (2013). Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv Drug Deliv Rev 65:24–35.
   PubMed Web of Science ®Google Scholar
• Kuroki Y, Takahashi H, Chiba H, Akino T. (1998). Surfactant proteins A and D: disease markers. Biochim Biophys Acta 1408:334–45.
   PubMed Web of Science ®Google Scholar
• Lin YS, Lee MY, Yang CH, Huang KS. (2015). Active targeted drug delivery for microbes using nano-carriers. Curr Top Med Chem 15:1525–31.
   PubMed Web of Science ®Google Scholar
• Manjappa AS, Chaudhari KR, Venkataraju MP, et al. (2011). Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release 150:2–22.
   PubMed Web of Science ®Google Scholar
• Maruyama K, Takizawa T, Yuda T, et al. (1995). Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta 1234:74–80.
   PubMed Web of Science ®Google Scholar
• Maybauer MO, Maybauer DM, Herndon DN. (2006). Incidence and outcomes of acute lung injury. N Engl J Med 354:416–7.
   PubMed Web of Science ®Google Scholar
• Mikawa K, Nishina K, Takao Y, Obara H. (2003). ONO-1714, a nitric oxide synthase inhibitor, attenuates endotoxin-induced acute lung injury in rabbits. Anesth Analg 97:1751–5.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. (2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53:283–318.
   PubMed Web of Science ®Google Scholar
• Park IN, Kim DS, Shim TS, et al. (2007). Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 132:214–20.
   PubMed Web of Science ®Google Scholar
• Paszko E, Senge MO. (2012). Immunoliposomes. Curr Med Chem 19:5239–77.
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, et al. (2011). An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Cottin V, Brown KK, Collard HR. (2015). Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J 46:512–20.
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Taniguchi H, Kondoh Y, et al. (2012). Acute exacerbation of IPF following diagnostic bronchoalveolar lavage procedures. Respir Med 106:436–42.
   PubMed Web of Science ®Google Scholar
• Schneider CA, Rasband WS, Eliceiri KW. (2012). NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671–5.
   PubMed Web of Science ®Google Scholar
• Siontorou CG. (2013). Nanobodies as novel agents for disease diagnosis and therapy. Int J Nanomed 8:4215–27.
   PubMed Web of Science ®Google Scholar
• Song JW, Hong SB, Lim CM, et al. (2011). Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 37:356–63.
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Omelyanenko VG, Papisov MI, et al. (1994). Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta 1195:11–20.
   PubMed Web of Science ®Google Scholar
• Wang SM, He X, Li N, et al. (2015). A novel nanobody specific for respiratory surfactant protein A has potential for lung targeting. Int J Nanomed 10:2857–69.
   PubMed Web of Science ®Google Scholar
• Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. (2015). Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release 200:138–57.
   PubMed Web of Science ®Google Scholar
• Wilson KC, Raghu G. (2015). The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF. Eur Respir J 46:883–6.
   PubMed Web of Science ®Google Scholar
• Zucker D, Marcus D, Barenholz Y, Goldblum A. (2009). Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties. J Control Release 139:73–80.
   PubMed Web of Science ®Google Scholar